Junko Tanizaki 研究室

主宰者：Junko Tanizaki

近畿大学

AI 要約（直近 5 年の研究成果）

本研究室は、主に遺伝子変異を持つ肺がんの治療抵抗性の成り立ちを解明し、より効果的な治療法の開発を目指しています。特に、特定の遺伝子変異（EGFR変異）を持つ非小細胞肺がん患者では、初期治療は有効でも、やがて薬が効かなくなる現象が起きます。本研究室では、この薬剤耐性がなぜ生じるのか、その仕組みを詳しく調べています。例えば、がん細胞内での遺伝情報の乱れ（染色体不安定性）が特定のシグナル伝達経路を活性化させ、治療薬への耐性を引き起こすメカニズムを明らかにしています。研究の手法としては、患者由来のがん細胞を用いた実験系と、患者の組織サンプルのゲノム・遺伝子発現解析を組み合わせています。細胞株での薬剤感受性試験や遺伝子改変実験を通じて、耐性の分子メカニズムを検証しており、また臨床データベースを用いた大規模な統計解析も行っています。加えて、新しい治療法の臨床試験設計や、免疫チェックポイント阻害剤などの最新治療における有害事象の管理に関する研究も実施しており、基礎的な知見から臨床応用まで幅広い視点から肺がん治療の課題に取り組んでいます。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（78 件）

[2026] Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)
DOI: https://doi.org/10.1016/j.ejca.2026.116684
[2026] Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report
DOI: https://doi.org/10.1186/s12890-026-04193-3
[2026] Development of Second Primary Malignancies in Long- term Survivors of Unresectable Esophageal Cancer
DOI: https://doi.org/10.21873/cdp.10534
[2026] Additional file 1 of Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report
DOI: https://doi.org/10.6084/m9.figshare.32039431
[2026] TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR -mutated locally advanced or metastatic non-small cell lung cancer
DOI: https://doi.org/10.1177/17588359261430561
[2026] Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer
DOI: https://doi.org/10.1016/j.lungcan.2026.109405
[2026] Additional file 1 of Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report
DOI: https://doi.org/10.6084/m9.figshare.32039431.v1
[2026] Abstract 2974: The anticancer effect of TROP2-targeted antibody-drug conjugates (ADC) is potentially attenuated by dysregulated cholesterol metabolism in cancer cells.
DOI: https://doi.org/10.1158/1538-7445.am2026-2974
[2025] TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib
[2025] TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib
DOI: https://doi.org/10.1177/17588359251385410

続きを表示（残り 68 件）

[2025] Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701603
[2025] Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701600
[2025] Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701609
[2025] Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701606
[2025] Figure S5 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701597
[2025] Figure S6 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701594
[2025] Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701579
[2025] Figure S7 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701591
[2025] Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701588
[2025] Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701585
[2025] Table S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701582
[2025] PT2.17.04 First Assessment of IASLC Inclusive Practices and Challenges: Results From the Diversity, Equity, and Inclusion Survey
DOI: https://doi.org/10.1016/j.jtho.2025.09.1182
[2025] TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps8647
[2025] Diagnostic and Therapeutic Challenges in an Older Patient With Concurrent Small-Cell Lung Carcinoma and Primary Duodenal Adenocarcinoma: A Case Report
DOI: https://doi.org/10.7759/cureus.83040
[2025] Abstract 424: Chromosomal instability leads to EGFR-TKI refractoriness via cGAS-STING activation in EGFR-mutated non-small cell lung cancer
DOI: https://doi.org/10.1158/1538-7445.am2025-424
[2025] Peritoneal Metastasis Mimicking Chemotherapy-Induced Complications in Lung Adenocarcinoma: A Diagnostic Challenge of a Case Report
DOI: https://doi.org/10.7759/cureus.82530
[2025] Paraneoplastic Syndromes Mimicking Dermatomyositis and Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Syndrome in Cancer of Unknown Primary Origin: A Case Report
DOI: https://doi.org/10.7759/cureus.81376
[2025] Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)
DOI: https://doi.org/10.1016/j.jtho.2025.02.026
[2025] Detection of Overlooked Rare <scp>EGFR</scp> Mutations in Non‐small Cell Lung Cancer Using Multigene Testing
DOI: https://doi.org/10.1111/1759-7714.70007
[2025] Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
DOI: https://doi.org/10.1016/s1470-2045(25)00001-4
[2025] 123TiP: TROPION-Lung14: A phase III study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC)
DOI: https://doi.org/10.1016/s1556-0864(25)00318-1
[2025] Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody
DOI: https://doi.org/10.3389/fonc.2025.1651248
[2025] Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer
DOI: https://doi.org/10.1016/j.lungcan.2025.108723
[2025] Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study
DOI: https://doi.org/10.1016/j.lungcan.2025.108633
[2025] PT2.14.03 Molecular Correlates of Response to Atezolizumab Plus Carboplatin and Paclitaxel in Patients With Thymic Carcinoma
DOI: https://doi.org/10.1016/j.jtho.2025.09.1167
[2025] Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
DOI: https://doi.org/10.3390/cells14060447
[2025] 124TiP: TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib
DOI: https://doi.org/10.1016/s1556-0864(25)00319-3
[2024] Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
DOI: https://doi.org/10.1172/jci168318
[2024] P4.11E.24 Clinical Features of Long-Term Response (LTR) to Immune Checkpoint Inhibitors (ICIs) in Patients with Advanced or Recurrent NSCLC
DOI: https://doi.org/10.1016/j.jtho.2024.09.737
[2024] LBA8 Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study
DOI: https://doi.org/10.1016/j.annonc.2024.10.657
[2024] 1O Exploration of gut microbiota biomarkers in treatment-naïve advanced NSCLC patients undergoing chemo-immunotherapy: Insights from the phase III trial, JCOG2007 (NIPPON)
DOI: https://doi.org/10.1016/j.iotech.2024.100885
[2024] Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain
DOI: https://doi.org/10.3892/mco.2024.2809
[2024] Immunotherapy for Lung Cancer: Update 2024
DOI: https://doi.org/10.2482/haigan.64.814
[2024] MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC
DOI: https://doi.org/10.1016/j.annonc.2024.07.515
[2024] 225P Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)
DOI: https://doi.org/10.1016/j.annonc.2024.08.2229
[2024] The impact of HRD mutation on survival in patients with KRAS-mutated advanced pancreatic cancer: A real-world database study.
DOI: https://doi.org/10.1200/jco.2024.42.23_suppl.221
[2024] A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.tps8656
[2024] Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3025
[2024] Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
DOI: https://doi.org/10.2147/lctt.s463429
[2024] Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
DOI: https://doi.org/10.1038/s41416-024-02662-2
[2024] First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study
DOI: https://doi.org/10.1093/jjco/hyad195
[2024] Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy
DOI: https://doi.org/10.1002/cnr2.1960
[2023] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
DOI: https://doi.org/10.1038/s41598-023-45337-3
[2023] 600TiP Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
DOI: https://doi.org/10.1016/j.annonc.2023.10.678
[2023] O16-5 Nivolumab for cancer of unknown primary (CUP): Initial results from an expanded access program (NivoCUP2, WJOG14620M)
DOI: https://doi.org/10.1016/j.annonc.2023.09.145
[2023] MO36-2 Updated analysis from a phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (NivoCUP)
DOI: https://doi.org/10.1016/j.annonc.2023.09.245
[2023] Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
DOI: https://doi.org/10.1016/j.jtocrr.2023.100590
[2023] 1501TiP A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
DOI: https://doi.org/10.1016/j.annonc.2023.09.2532
[2023] Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain
DOI: https://doi.org/10.3892/ol.2023.13941
[2023] Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)
DOI: https://doi.org/10.1016/j.jtho.2023.06.012
[2023] Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)
DOI: https://doi.org/10.1016/j.cllc.2023.05.004
[2022] The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
DOI: https://doi.org/10.1016/j.jtocrr.2022.100373
[2022] The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease
DOI: https://doi.org/10.1016/j.resinv.2022.05.004
[2022] Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e21175
[2022] The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e21177
[2021] HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.ccr-21-3359
[2021] A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
DOI: https://doi.org/10.1158/1078-0432.ccr-21-3194
[2021] A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
DOI: https://doi.org/10.1016/j.jtocrr.2021.100265
[2021] Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer
DOI: https://doi.org/10.1016/j.ejca.2021.11.011
[2021] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
DOI: https://doi.org/10.1016/j.annonc.2021.11.009
[2021] Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
DOI: https://doi.org/10.1111/cas.15176
[2021] KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
DOI: https://doi.org/10.1158/1078-0432.ccr-21-0856
[2021] MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L
DOI: https://doi.org/10.1016/j.annonc.2021.05.569
[2021] MO4-1 EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402
DOI: https://doi.org/10.1016/j.annonc.2021.05.567
[2021] O3-1 A phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (CUP) (NivoCUP)
DOI: https://doi.org/10.1016/j.annonc.2021.05.525
[2021] CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib
DOI: https://doi.org/10.1007/s10147-021-01947-3
[2021] A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.9037
[2021] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
DOI: https://doi.org/10.1186/s12890-021-01523-5

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（78 件）

科研費（0 件）

所属学会・役職（0 件）